Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Lockdown Living May Cause A Third Of Brits More Pain As New Prevention Guidance Issued


News provided by

Nurofen

12 Oct, 2020, 23:01 GMT

Share this article

Share toX

Share this article

Share toX

A new study by Nurofen has uncovered that 36% of Brits have experienced new or increased pains during lockdown, even for those who seized the opportunity to swap the commute for more leisure & family time

- Across the country, many Brits may have discovered there were some benefits to lockdown living and made the most of working from home, spending more time with family and doing leisure activities but many have also found themselves experiencing more acute pain than they did before lockdown began.[1]

- Over 1/3 of people reported an increase in pain since the beginning of lockdown in March, with 36% citing an increase in back aches, 34% headaches, 27% joint pains, 26% neck aches, and 24% muscle pains.[1] Key drivers included more stress, increased screen time & poor work from home set ups – all which could have stemmed from changes in lifestyle during lockdown living[1] 

- 60% of individuals say they want more advice on how to deal with their pain[1]

- Nurofen are reminding people to follow NHS guidance and have developed the '3P's of acute pain management' to help people live a life with less pain

SLOUGH, England, Oct. 12, 2020 /PRNewswire/ -- New findings by Nurofen have found that lockdown living has led to new acute pains across the UK. While lockdown has been challenging, for some it also brought unexpected opportunities including more time for family, leisure or working from home. However, the results show that for many across the UK, these opportunities may have contributed to a rise in acute pain perhaps as much as the negative factors of lockdown did.

The survey suggests that people are taking pain relief into their own hands by relying on self-care methods more, such as rest, relaxation and exercise. Less people have sought advice from GPs and pharmacists, as access to health professionals has been limited.[1],[2],[3] Given many believe these everyday pains will not lessen in the near future,1 there is a need for people to learn how to help manage their pain and take positive steps towards appropriately treating or preventing it.  

New acute pain during lockdown impacted respondents across all regions in the UK, showing that the country is facing these challenges together. Whilst lockdown enabled people to spend more time at home with their families, this may have increased pain suffering as 12% of respondents attributed new discomfort to increased childcare hours.[1] Younger people (aged 25 – 44) said they experienced more back pains and headaches, in comparison to those over 45.[1] This age group were also more likely to claim that their increased pain was caused by a poor work from home set up and more time looking after their children; perhaps as a result of juggling work with home schooling.[1] On top of this, 50% of all respondents claimed stress was a key factor in their increased pain[1], which might have been a reflection of the lockdown climate.

DIY and gardening, which may have been a result of new found leisure time was cited by more than a fifth (21%) as causing more acute pain.[1] As the UK's workforce relocated from their offices to their homes, the flexibility of no commute was tempered with a quarter of respondents putting their new 'lockdown pain' down to a poor office or workstation set-up at home.[1]

Many may have taken the opportunity during lockdown to indulge on a favourite TV series or film, however, 39% believed this increased time spent in front of TVs, computers or laptops caused their pain.[1] In fact, more screen time may also have had other consequences, with 35% believing changing sleep patterns and 33% thought less physical activity also worsened their pain.[1], [4], [5] Some people used the new time gained to improve their health and fitness during lockdown, but this may have led to further pain as 16% of respondents felt exercise had increased their aches.1

"Pain can affect our mood, relationships, family and work life so it's important that we take steps to deal with it quickly and effectively," commented Dr Sarah Jarvis MBE, a general practitioner.* "It's clear that adjusting to new ways of living and working has heightened our acute pains, or even caused new ones. It is vital that people deal with their pain early to avoid suffering unnecessarily and rely on trusted sources, such as the NHS or a pharmacist to understand the best solution for their individual needs."

The survey also found that since lockdown 21% and 17% fewer people have sought advice from GPs and Pharmacists respectively.[1] This may have resulted in 60% of these respondents wanting more information on how to manage their pain.[1]

Nurofen are committed to helping people better understand and manage their acute, short-term pain, especially during this critical time. As such, Nurofen recommends people follow the three Ps of acute pain management, in line with NHS guidance:

Proactivity – Be proactive, don't let acute pain persist

  • Identify pain triggers and address them
  • Be conscious of your pain and take action

Pain relief – Take positive steps to find the solution that works for you

  • Take gentle exercise, breathe right, relax and stretch[6]
  • The NHS recommends over-the-counter medications such as ibuprofen and paracetamol to treat a range of aches, pains and inflammation[7],[8]
  • If pain persists, seek advice from a healthcare professional7

Prevention – Help to avoid future pain occurring

  • Understand your pain and how to manage it
  • For more information on managing pain, please visit the NHS website: https://www.nhs.uk/live-well/healthy-body/10-ways-to-ease-pain/ or speak to your GP or pharmacist

Nikki, a parent working from home during lockdown who experienced new pains said: "Lockdown was quite a roller coaster. It was great to spend more time with the children however working from home, schooling the kids and juggling family life was stressful and led to headaches and tension pains. I've always been fit and healthy so these pains were completely unexpected especially as I never had any issues with pain in the past."

"Going to the GP wasn't an option, so I just tried to manage it at home by trying to find time to relax when I could or take medication bought in a supermarket despite being unsure if these things would help. So many people must have been going through what I experienced, and it amazes me that there isn't more advice and support relating to pain during lockdown."

Although some are taking more ownership of their pain management, many think their back pain (38%) or headaches (35%) will not change in the near future.1 As people think their pains will persist, there is a heightened importance in being equipped with treatment methods and correct behaviours to help prevent acute pain.

"At Nurofen we recognise that acute pain can be an inevitable part of life, but it shouldn't take over people's lives," commented Sezi Unluturk, Category Manager, Nurofen. "With the future still uncertain and life not yet back to normal, it is more important than ever that we continue to offer support and guidance. Our three Ps of Proactivity, Pain relief and Prevention provide holistic guidance to help people approach pain management confidently and safely so they can get on with their lives."

About the survey

The research was carried out online by RWB between 31st July 2020 and 3rd August 2020. The sample comprised 2,000 UK adults who have experienced pains since lockdown. All research conducted adheres to the UK Market Research Society (MRS) code of conduct (2019). RWB is registered with the Information Commissioner's Office and complies with the DPA (1998)

About Nurofen

Nurofen is the original over the counter ibuprofen, bringing the pioneering benefits of ibuprofen to consumers for the first time, and has been providing effective pain relief to millions of families ever since.

Nurofen are there to help people manage their pain, so that they can continue to do the things they love without discomfort. In understanding that not all pains are the same, by putting people first, Nurofen are able to provide relief for all manner of acute pains. Nurofen believe that everyone should be able to live life with less pain.

Find out more and explore the products on the Nurofen website: www.nurofen.co.uk

*Dr Sarah Jarvis does not endorse Nurofen or other pain medications.

References

[1] RWB survey. July 2020.

[2] GP Online. Face-to-face GP consultations up 70% since start of lockdown. Available at: https://www.gponline.com/face-to-face-gp-consultations-70-start-lockdown/article/1689441 [ Accessed September 2020].

[3] The Pharmaceutical Journal. Nearly a third of people more likely to visit their pharmacy first following COVID-19 pandemic. Available at: https://www.pharmaceutical-journal.com/news-and-analysis/news/nearly-a-third-of-people-more-likely-to-visit-their-pharmacy-first-following-covid-19-pandemic/20208201.article ]

[4] Headache, back pain, sleep deprivation: Prolonged screen use during Coronavirus lockdown can have detrimental effects. Available at: https://www.firstpost.com/health/headache-back-pain-sleep-deprivation-prolonged-screen-use-coronavirus-lockdown-can-detrimental-effects-8391441.html  [Accessed September 2020].

[5] Stretch to ease screen-time-related neck and shoulder pain. Available at: https://www.health.harvard.edu/healthbeat/stretch-to-ease-screen-time-related-neck-and-shoulder-pain [Accessed September 2020].

[6] NHS. 10 ways to reduce pain. Available at: https://www.nhs.uk/live-well/healthy-body/10-ways-to-ease-pain/?tabname=body. [Accessed September 2020].

[7] NHS. Which painkiller? Available at: https://www.nhs.uk/live-well/healthy-body/which-painkiller-to-use/. [Accessed September 2020]

[8] NHS. Ibuprofen for adults. Available at: https://www.nhs.uk/medicines/ibuprofen-for-adults/ [Accessed September 2020].

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.